

EBMT SURVEY ON TRANSPLANT AND CELLULAR THERAPY ACTIVITY 2022

Table 1: Report the number of **patients** receiving their 1st allogeneic and/or 1st autologous transplant in 2022 in rows 1-30. Report non 1st HSCT in row 32.

Table 2: Report the number of **patients** receiving non HSCT cellular therapies in 2022 by indication and cell type in rows 37-45.

Table 1: Row 1-31		HLA-id sibling			Twin	Haplo (≥ 2 loci mismatch)		Other family member			Unrelated			Autologous			Total Allo	Total Auto	Total HSCT	No. allo after auto
		BM	PBSC	Cord	All	BM	PBSC	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord				
1	AML 1st CR																			
2	AML non 1st CR																			
3	AML: therapy or MDS related																			
4	ALL 1st CR																			
5	ALL non 1st CR																			
6	CML 1st cP																			
7	CML non 1st cP																			
8	MDS or MDS/MPN																			
9	MPN																			
10	CLL incl. PLL																			
11	PCD - Myeloma																			
12	PCD - other																			
13	Hodgkin Lymphoma																			
14	DLBCL NHL (all types)																			
15	Other B-cell NHL																			
16	T-cell NHL																			
17	Neuroblastoma																			
18	Soft tissue/Ewing sarcoma																			
19	Germ cell tumor																			
20	Other solid tumor																			
21	BM aplasia - SAA																			
22	BM aplasia - other																			
23	Thalassemia																			
24	Sickle cell disease																			
25	Primary immune deficiency																			
26	Inh. disorders of metabolism																			
27	Auto immune disease - MS																			
28	Auto immune disease - SSC																			
29	Auto immune disease - other																			
30	Others (incl. Histiocytosis)																			
31	Total 1st HSCT (=row 1-30)																			
32	Additional non 1st HSCT																		X	
33	Total all HSCT (=row 31+32)																			
34	No. patients aged <18 reported in row 1-30																			
35	Number of Non-Myeloablative (incl. RIC) allogeneic transplants in 2022																			

36 Number patients with unmanipulated DLI infusions in 2022:	For graft enhancement/failure:	For residual disease:	For relapse:	Per protocol:
---	--------------------------------	-----------------------	--------------	---------------

Table 2: Number of patients with non HSCT cellular therapies using manipulated or selected cells (excluding DLI) in 2022	CAR T cells		selected/expanded T cells or CIK		Regulatory T cells (TREGS)		Other genetically modified T cells		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Genetically modified CD34+		Other therapies (incl. boosts)		
	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	
37	X																				
38	X																				
39																					
40																					
41																					
42																					
43																					
44																					
45																					

Signature